Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.
暂无分享,去创建一个
C. Frampton | A. Richards | E. Espiner | M. Nicholls | H. Ikram | I. Crozier | T. Yandle | T. Kosoglou | M. Rallings | A. Richards
[1] G. Wittert,et al. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. , 1992, Circulation research.
[2] E. Espiner,et al. Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. , 1992, Clinical chemistry.
[3] J. Connell,et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension , 1992, Journal of hypertension.
[4] C. Frampton,et al. Acute Inhibition of Endopeptidase 24.11 in Essential Hypertension: SCH 34826 Enhances Atrial Natriuretic Peptide and Natriuresis Without Lowering Blood Pressure , 1992, Journal of cardiovascular pharmacology.
[5] N. Markandu,et al. Dietary Sodium and Inhibition of Neutral Endopeptidase 24.11 in Essential Hypertension , 1991, Hypertension.
[6] G. Wittert,et al. Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects. , 1991, Journal of hypertension.
[7] M. Burnier,et al. Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers , 1991, Clinical pharmacology and therapeutics.
[8] G. Wittert,et al. EC 24.11 inhibition in man alters clearance of atrial natriuretic peptide. , 1991, The Journal of clinical endocrinology and metabolism.
[9] P. Chiu,et al. Neutral metalloendopeptidase inhibition: a novel means of circulatory modulation. , 1990, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[10] E. H. Blaine,et al. Chronic Atriopeptin Regulation of Arterial Pressure in Conscious Hypertensive Rats , 1990, Hypertension.
[11] L. Field,et al. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. , 1990, Hypertension.
[12] C. Frampton,et al. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. , 1990, Hypertension.
[13] J. Schwartz,et al. Antihypertensive activity of sinorphan , 1990, The Lancet.
[14] N. Glorioso,et al. Low-dose infusion of atrial natriuretic factor in mild essential hypertension. , 1989, Circulation.
[15] D. Northridge,et al. EFFECTS OF UK 69 578: A NOVEL ATRIOPEPTIDASE INHIBITOR , 1989, The Lancet.
[16] C. Foster,et al. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. , 1989, The Journal of pharmacology and experimental therapeutics.
[17] R. Neubeck,et al. Potentiation of the Depressor Responses to Atrial Natriuretic Peptides in Conscious SHR by an Inhibitor of Neutral Endopeptidase , 1989, Journal of cardiovascular pharmacology.
[18] P. Ellis,et al. Atriopeptidase inhibitors a novel class of drugs that raises levels of endogenous atrial natriuretic factor the preclinical pharmacology of uk 69578 , 1989 .
[19] D. de Zeeuw,et al. Antihypertensive Effect of a 5‐Day Infusion of Atrial Natriuretic Factor in Humans , 1989, Hypertension.
[20] W. P. Dixon,et al. BMPD statistical software manual , 1988 .
[21] A. Kenny,et al. Role of endopeptidase‐24.11 in the inactivation of atrial natriuretic peptide , 1988, FEBS letters.
[22] A. Richards,et al. Low dose infusions of 26- and 28-amino acid human atrial natriuretic peptides in normal man. , 1988, The Journal of clinical endocrinology and metabolism.
[23] H. Zurcher-Neely,et al. Inactivation of atrial natriuretic factor by the renal brush border. , 1987, Biochimica et biophysica acta.
[24] M. Cantin,et al. Body Fluids and Plasma Atrial Peptide After Its Chronic Infusion in Hypertensive Rats , 1987, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[25] D. Murphy,et al. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. , 1986, Clinical chemistry.
[26] E. Espiner,et al. Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. , 1986, The Journal of clinical endocrinology and metabolism.
[27] M. Cantin,et al. Chronic Infusion of Low Doses of Atrial Natriuretic Factor (ANF Arg 101-Tyr 126) Reduces Blood Pressure in Conscious SHR without Apparent Changes in Sodium Excretion , 1985, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[28] E. Espiner,et al. A direct radioimmunoassay for aldosterone in plasma. , 1983, Clinical chemistry.
[29] Nicholls Mg,et al. A sensitive, rapid radioimmunoassay for angiotensin II. , 1976 .
[30] P. Dunn,et al. Outpatient screening tests for primary aldosteronism. , 1976, Australian and New Zealand journal of medicine.
[31] E. Espiner,et al. A sensitive, rapid radioimmunoassay for angiotensin II. , 1976, The New Zealand medical journal.
[32] A. Steiner. Radioimmunoassay for the cyclic nucleotides. , 1973, Pharmacological reviews.
[33] C W Parker,et al. Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. , 1972, The Journal of biological chemistry.
[34] A. Vander. Effect of catecholamines and the renal nerves on renin secretion in anesthetized dogs. , 1965, The American journal of physiology.